Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Culling The Pipeline: An Analysis Of Biogen's Discontinued Programs

You may also be interested in...

Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?

The big biotech announces Steve Holtzman, former chairman of Infinity, as head of corporate development, with Doug Williams, former CEO of ZymoGenetics stepping in as exec VP of R&D.

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.

Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts